共 50 条
- [2] Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine encapsulated stent for treatment of native coronary artery lesions:: Clinical and angiographic results of the ENDEAVOR II trialCIRCULATION, 2006, 114 (08) : 798 - 806Fajadet, JeanWijns, WilliamLaarman, Gert-JanKuck, Karl-HeinzOrmiston, JohnMunzel, ThomasPopma, Jeffrey J.Fitzgerald, Peter J.Bonan, RaoulKuntz, Richard E.
- [3] ENDEAVOR II – Long-Term Efficacy and SafetyRandomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions – Long-Term Efficacy and Safety of the ENDEAVOR II Trial – Randomisierte multizentrische Doppelblindstudie zur Behandlung der stenosierenden koronaren Herzerkrankung mit dem neuen zotarolimusbeschichteten Stent im Vergleich zum herkömmlichen Koronarstent mit cobalthaltiger Legierung – Langzeiteffektivität und Sicherheit nach 3 Jahren – ENDEAVOR II Herz Kardiovaskuläre Erkrankungen, 2007, 32 (5) : 428 - 428
- [4] Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II studyEUROINTERVENTION, 2010, 6 (05) : 562 - 567Fajadet, JeanWijns, WilliamLaarman, Gert-JanKuck, Karl-HeinzOrmiston, JohnBaldus, StephanHauptmann, Karl E.Suttorp, Maarten D.Drzewiecki, JanuszPieper, MichaelSchultheiss, Heinz-PeterMauri, Laura
- [5] The safety and efficacy of the endeavor zotarolimus-eluting stent system in Japanese patients with symptomatic coronary artery disease: ENDEAVOR Japan at 9 monthsAMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (8A): : 161L - 161LSato, Shigeru
- [6] First-in-human safety and efficacy study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system: Endeavor I 24-month multicenter experienceAMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (7A): : 181H - 182HMeredith, IOrmiston, JWhitborn, R
- [7] A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions 12-Month Outcomes From the ENDEAVOR IV TrialJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (06) : 543 - 554Leon, Martin B.Mauri, LauraPopma, Jeffrey J.Cutlip, Donald E.Nikolsky, EugeniaO'Shaughnessy, CharlesOverlie, Paul A.McLaurin, Brent T.Solomon, Stuart L.Douglas, John S., Jr.Ball, Michael W.Caputo, Ronald P.Jain, AshTolleson, Thaddeus R.Reen, Bernard M., IIIKirtane, Ajay J.Fitzgerald, Peter J.Thompson, KweliKandzari, David E.
- [8] The endeavor zotarolimus-eluting stent in patients with native coronary artery disease: Safety with 1200 patients followed to three yearsJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : B46 - B46Mauri, LauraLeon, Martin B.Wijns, WilliamFajadet, JeanMeredith, Ian
- [9] Long-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent 3-Year Results From the ENDEAVOR III Trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1199 - 1207Eisenstein, Eric L.Leon, Martin B.Kandzari, David E.Mauri, LauraEdwards, RexKong, David F.Cowper, Patricia A.Anstrom, Kevin J.
- [10] Endeavor II 12-month clinical results: A randomized, double-blind, multicenter trial of the endeavor ABT-578-eeluting stent system for treatment of native coronary arteriesAMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (7A): : 181H - 181HWijns, WFajadet, JKuntz, RLaarman, GJKuck, KHOrmiston, J